Diroximel is a prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MedsAcross supplies Diroximel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: US FDA prescribing information
The mechanism by which diroximel fumarate exerts its therapeutic effect in multiple sclerosis is unknown. MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
Source: US FDA prescribing information
Blood tests are required prior to initiation of VUMERITY. Starting dose: 231 mg twice a day, orally, for 7 days. Maintenance dose after 7 days: 462 mg (administered as two 231 mg capsules) twice a day, orally. Swallow VUMERITY capsules whole and intact. Do not crush, chew, or sprinkle capsule contents on food. Avoid administration of VUMERITY with a high-fat, high-calorie meal/snack. Avoid co-administration of VUMERITY with alcohol
Source: US FDA prescribing information
VUMERITY is contraindicated in patients With known hypersensitivity to diroximel fumarate, dimethyl fumarate, or to any of the excipients of VUMERITY. Reactions may include anaphylaxis and angioedema. Taking dimethyl fumarate. Known hypersensitivity to diroximel fumarate, dimethyl fumarate, or to any of the excipients of VUMERITY. Co-administration with dimethyl fumarate
Source: US FDA prescribing information
Anaphylaxis and Angioedema: Discontinue and do not restart VUMERITY if these occur. Progressive Multifocal Leukoencephalopathy (PML): Withhold VUMERITY at the first sign or symptom suggestive of PML. Herpes Zoster and Other Serious Opportunistic Infections: Consider withholding VUMERITY in cases of serious infection until the infection has resolved. Lymphopenia: Obtain a CBC including lymphocyte count before initiating VUMERITY, after 6 months, and every 6 to 12 months thereafter. Consider interruption of VUMERITY if lymphocyte counts <0.5 × 10 9 /L persist for more than six months. Liver Injury: Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating VUMERITY and during treatment, as clinically indicated. Discontinue VUMERITY if clinically significant liver injury induced by VUMERITY is suspected.
Source: US FDA prescribing information
The following important adverse reactions are described elsewhere in labeling: Anaphylaxis and Angioedema Progressive Multifocal Leukoencephalopathy Herpes Zoster and Other Serious Opportunistic Infections Lymphopenia Liver Injury Flushing Serious Gastrointestinal Reactions Most common adverse reactions (incidence for dimethyl fumarate [which has the same active metabolite as VUMERITY] ≥10% and ≥2% more than placebo) were flushing, abdominal pain, diarrhea, and nausea.
Source: US FDA prescribing information
Concomitant Dimethyl Fumarate VUMERITY is contraindicated in patients currently taking dimethyl fumarate, which is also metabolized to monomethyl fumarate. VUMERITY may be initiated the day following discontinuation of dimethyl fumarate.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Diroximel, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Vumerity 231 mg capsuleOral | Biogen | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Diroximel and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Diroximel, including Vumerity.
Yes. The US FDA first approved Diroximel on 29 October 2019, according to Drugs@FDA.
Yes. Diroximel has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Diroximel is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Diroximel is classified under ATC code L04AX07 (Dimethyl).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.